



OPEN ACCESS

EDITED BY

Andrea Ladányi,
National Institute of Oncology (NIO),
Hungary

*CORRESPONDENCE

Gábor Rubovszky,
rubovszkyg@gmail.com

†These authors have contributed equally
to this work and share first authorship

‡Panel members are listed in the
Supplementary Appendix

RECEIVED 18 November 2022

ACCEPTED 19 January 2023

PUBLISHED 31 January 2023

CITATION

Rubovszky G, Kocsis J, Boér K,
Chilingirova N, Dank M, Kahán Z,
Kaidarova D, Kövér E, Krakovská BV,
Máhr K, Mriňáková B, Pikó B,
Božović-Spasojević I and Horváth Z
(2023), Corrigendum: Systemic
treatment of breast cancer. 1st Central-
Eastern European professional
Consensus Statement on breast cancer.
Pathol. Oncol. Res. 29:1610954.
doi: 10.3389/pore.2023.1610954

COPYRIGHT

© 2023 Rubovszky, Kocsis, Boér,
Chilingirova, Dank, Kahán, Kaidarova,
Kövér, Krakovská, Máhr, Mriňáková,
Pikó, Božović-Spasojević and Horváth.
This is an open-access article
distributed under the terms of the
Creative Commons Attribution License
(CC BY). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Systemic treatment of breast cancer. 1st Central-Eastern European professional Consensus Statement on breast cancer

Gábor Rubovszky^{1*†}, Judit Kocsis^{2†}, Katalin Boér³,
Nataliya Chilingirova⁴, Magdolna Dank⁵, Zsuzsanna Kahán⁶,
Dilyara Kaidarova⁷, Erika Kövér⁸, Bibiana Vertáková Krakovská^{9,10},
Károly Máhr¹¹, Bela Mriňáková^{9,10}, Béla Pikó¹²,
Ivana Božović-Spasojević¹³ and Zsolt Horváth² on behalf of the
Central-Eastern European Academy of Oncology (CEEAO)
International Professional Panel[‡]

¹Department of Clinical Pharmacology, National Institute of Oncology, Chest and Abdominal Tumours
Chemotherapy "B", Budapest, Hungary, ²Center of Oncoradiology, Bács-Kiskun County Teaching
Hospital, Kecskemét, Hungary, ³Department of Oncology, Szent Margit Hospital, Budapest, Hungary,
⁴Clinic Center of Excellence, Heart and Brain Hospital, Science and Research Institute, Medical
University-Pleven, Pleven, Bulgaria, ⁵Oncology Centre, Semmelweis University, Budapest, Hungary,
⁶Oncotherapy Clinic, University of Szeged, Szeged, Hungary, ⁷Kazakh Institute of Oncology and
Radiology, Almaty, Kazakhstan, ⁸Institute of Oncotherapy, Faculty of Medicine, University of Pécs,
Pécs, Hungary, ⁹1st Department of Oncology, Faculty of Medicine, Comenius University, Bratislava,
Slovakia, ¹⁰Medical Oncology Department, St. Elisabeth Cancer Institute, Bratislava, Slovakia,
¹¹Department of Oncology, Szent Rafael Hospital of Zala County, Zalaegerszeg, Hungary, ¹²County
Oncology Centre, Pándy Kálmán Hospital of Békés County Council, Gyula, Hungary, ¹³Institute for
Oncology and Radiology of Serbia, Daily Chemotherapy Hospital, Belgrade, Serbia

KEYWORDS

early breast cancer, locally advanced breast cancer, adjuvant treatment, neoadjuvant
treatment, metastatic breast cancer, inflammatory breast cancer, guideline

A Corrigendum on Systemic treatment of breast cancer. 1st Central-Eastern European professional consensus statement on breast cancer

by Rubovszky G, Kocsis J, Boér K, Chilingirova N, Dank M, Kahán Z, Kaidarova D, Kövér E,
Krakovská BV, Máhr K, Mriňáková B, Pikó B, Božović-Spasojević I and Horváth Z (2022). *Pathol.*
Oncol. Res. 28:1610383. doi: 10.3389/pore.2022.1610383

In the original article, the reference for 118 was incorrectly written as:

“Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, et al. Phase III,
Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2)
Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase

Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2018;36(8):741-8.”

It should be

“Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2)

Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. *J Clin Oncol*. 2021;39(1):79-89. doi: 10.1200/JCO.20.01894.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.